Microphthalmia-associated transcription factor (Mitf
Microphthalmia-associated transcription factor (Mitf), 1 encoded by the mouse Mitf locus, plays a critical role in the differentiation of various cell types, including neural crestderived melanocytes, bone marrow-derived mast cells and osteoclasts, and optic cup-derived retinal pigment epithelium (RPE) (1) (2) (3) . Mitf and its human counterpart, MITF, contain a basic helix-loop-helix leucine zipper structure, which is required for DNA binding and dimer formation. MITF consists of at least five isoforms with distinct amino termini, called MITF-A, -B, -C, -H, and -M (4 -6). The amino termini of these isoforms are encoded by a separate first exons, and each exon 1 is under the control of a unique promoter (6) . Among these isoforms, MITF-M/Mitf-M is exclusively expressed in melanocytes and melanoma cells of neural crest origin (4, 5, 7) . In fact, the 5Ј-flanking region of the first exon, coding for the amino terminus of MITF-M, shows the melanocyte-specific promoter function (8) , here referred to as the MITF-M promoter. In contrast, other MITF isoforms are widely expressed in many cell types (4, 5) .
MITF-M/Mitf-M efficiently transactivates the melanogenesis enzyme genes, such as tyrosinase and tyrosinase-related protein-1, in cultured cells (9 -14) and can convert a fibroblast cell line to the cells expressing tyrosinase and tyrosinase-related protein-1 (15) . The mutations in the MITF/Mitf gene were found in patients with auditory pigmentary syndromes such as Waardenburg syndrome type 2 (16 -18) , as well as in many Mitf mutant mice (2) . These affected individuals mainly exhibit hypopigmentation and hearing impairment, caused by the lack of pigment cells in the skin and inner ear. Moreover, the MITF-M promoter is up-regulated by PAX3 (19), a transcription factor with a paired-homeodomain, in which the gene is responsible for Waardenburg syndrome types 1 and 3 (17) . Moreover, the essential requirement of Mitf-M in melanocyte development was verified by the molecular lesion of the blackeyed white Mitf mi-bw mice (20) , which are characterized by a completely white coat color, deafness, and normally pigmented RPE (21) . In Mitf mi-bw mice, the insertion of an L1 retrotransposable element in intron 3 lead to complete repression of Mitf-M mRNA expression and to a reduction of Mitf-A and Mitf-H mRNAs expression (20) . Taken together, these results indicate that MITF-M/Mitf-M is a key regulator of the melanocyte development but is dispensable for RPE development. However, the mechanism of differentiation of neural crest cells toward melanocytes is not well understood.
Wnt proteins, which are secreted cysteine-rich glycoproteins, have been established as developmentally important signaling molecules (22) . Particularly, Wnt-1 and Wnt-3a are required for the expansion of neural crest precursors (23, 24) and for determining the fate of neural crest cells during early development (25) . In fact, targeted disruption of the Wnt-1 and Wnt-3a genes in the mouse causes deficiency of neural crest derivatives, including melanocytes (24) . On the other hand, mutant mice lacking Wnt-1 or Wnt-3a show no noticeable deficiency of neural crest derivatives from the dorsal neural tube (26, 27) . These results suggest a redundant role for Wnt-1 and Wnt-3a signaling in the differentiation of neural crest precursors. Wnt-3a is expressed in pluripotent ectoderm cells of the primitive streak during gastrulation (27) . The onset of Wnt-3a expression is detected at embryonic day 7.5 (27) , which precedes the onset of Mitf expression in neural crest cells (9.5-10.5 days) (28) . These results suggest that Wnt-3a is a good candidate for regulating the differentiation of neural crest cells toward melanocytes. The signals evoked by Wnt proteins lead to intracel-* This work was supported in part by grants-in-aid for scientific research (B), for exploratory research, and for encouragement of young scientist (to K. Y.) from the Ministry of Education, Science, Sports and Culture of Japan. This work was also supported in part by the Nakatomi Foundation and the Kao Foundation for Arts and Sciences. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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Here, we show that exogenously added Wnt-3a protein induces endogenous Mitf-M mRNA in cultured melanocytes. In addition, we identify the functional LEF-1-binding site in the MITF-M promoter and provide evidence that Wnt-3a signaling recruits ␤-catenin and LEF-1 to the MITF-M promoter, which leads to increased transcription from the MITF-M promoter. Therefore, the present study shows a direct link between Wnt signaling and Mitf-M/MITF-M expression.
EXPERIMENTAL PROCEDURES
Wnt-3a Conditioned Medium-The mouse fibroblast L cells, constitutively expressing mouse Wnt-3a cDNA, were seeded at a density of 1 ϫ 10 6 in a 94-mm dish containing a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F12 supplemented with 10% fetal calf serum (30) . After 3 days of culture, cells were refed with fresh medium and incubated for 1 more day, and the cultured media were collected as conditioned media, referred to as Wnt3a/L-CM. Wnt3a/L-CM was estimated to contain about 400 ng/ml of Wnt-3a protein (30) . Conditioned media, neo/L-CM, were also prepared from the cultures of control L cells that were stably transfected with a vector plasmid as described previously (30) .
Northern Blot Analysis-Melan-a murine-immortalized melanocytes, a gift from D. C. Bennett (31) , were grown in minimum essential medium supplemented with 10% fetal calf serum and 200 nM phorbol 12-myristate 13-acetate. Melan-a cells, maintained in a 3.5-cm dish containing 1 ml of the medium, were treated with Wnt3a/L-CM or neo/L-CM for 24 h. The final concentration of Wnt-3a was about 40 ng/ml. Total RNA was prepared from the treated Melan-a cells of two dishes and subjected to Northern blot analysis as described previously (15) . The ClaI/EcoRI DNA fragment of human MITF cDNA (32) and glyceraldehyde 3Ј-phosphate dehydrogenase cDNA (positions 601-1052) (33) were labeled with [␣-32 P]dCTP using a BcaBEST labeling kit (Takara) and were used as hybridization probes.
Plasmid Preparation-A wild-type reporter plasmid, pGL3-MITF/M, was constructed as follows. The BamHI/XhoI fragment containing the 2.2-kilobase pair human MITF-M pomoter was isolated from pHMIL1 (8) and ligated to pGL3-Basic (Promega), linearized by the digestion with SmaI and XhoI. Prior to ligation, the BamHI site had been converted to a blunt end by a filling-in reaction. A mutant construct, pGL3-MITF/M(m195), was constructed from pGL3-MITF/M by the QuickChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. The mutant primer used was the synthetic oligonucleotide (positions Ϫ215 to Ϫ174) carrying the base changes at positions Ϫ196 and Ϫ195. Thus, pGL3-MITF/M(m195) carries the GT nucleotides instead of the original TG nucleotides at position Ϫ195 (8).
Human LEF-1 cDNA, a gift from K. A. Jones (34) , was subcloned in the pRc/CMV eukaryotic expression vector (Invitrogen), yielding pRc/ CMV-LEF-1. A dominant-negative form of LEF-1, DNLEF-1, lacks the 26 amino acid residues near the amino terminus (amino acid positions 2-27); its cDNA was made by polymerase chain reaction and subcloned in pRc/CMV, generating pRc/CMV-DNLEF-1. ␤-Catenin cDNA was synthesized by reverse-transcribed polymerase chain reaction and subcloned in pRc/CMV, yielding pRc/CMV-␤-catenin. TOPFLASH and FOPFLASH, gifts from M. van de Wetering and H. Clevers (35) , contain the LEF-1 responsive elements and the mutated LEF-1 responsive elements, respectively.
Electrophoretic Mobility Shift Assay (EMSA)-LEF-1 protein was produced from pRc/CMV-LEF-1 by in vitro transcription/translation reaction using a TNT T7-coupled reticulocyte lysate system kit (Promega). The production of LEF-1 protein was assessed by electrophoresis of the translation products labeled with [
35 S]methionine. The wild-type oligonucleotide of the MITF promoter sequence from nucleotides Ϫ215 to Ϫ174 (5Ј-CTGACAGTGAGTTTGACTTTGATAGCTCGTCACTTAA-AAAGG-3Ј/3Ј-GACTGTCACTCAAACTGAAACTATCGAGCAGTGAAT-TTTTCC-5Ј) was end-labeled with [␥-
32 P]ATP and T4 polynucleotide kinase and used as a probe. EMSA was carried out as described previously (18) .
Transfection and Luciferase Assay-HeLa cells were grown in minimum essential medium supplemented with 10% fetal calf serum. HMV-II melanoma cells were grown in Ham's F12 medium supplemented with 10% fetal calf serum. HeLa cells were seeded at 60 -80% confluency in a 3.5-cm dish 18 -24 h prior to transfection. Transfection was performed by the calcium phosphate precipitation method (18) . The amount of DNA used for transfection was 6 g, consisting of 0.5 g of each test plasmid and pCH110, ␤-galactosidase expression vector under control of SV40 early promoter as an internal control, and pBluescript SK(ϩ) as a filler. Transfection was also carried out in HMV-II melanoma cells as described above. After 24 h, transfected cells were harvested, and the activities of luciferase and ␤-galactosidase were measured as described previously (13) . Luciferase activity was normalized by ␤-galactosidase activity.
Melan-a cells were transfected by FuGene 6 transfection reagent (Roche Molecular Biochemicals) according to the manufacturer's instructions. The amount of DNA used for transfection was 1.5 g, consisting of 0.5 g of each test plasmid and pCH110, with pBluescript SK(ϩ) as a filler. After 4 h, Wnt3a/L-CM or neo/L-CM was added to each culture medium of transfected Melan-a cells. Cells were then incubated for 24 h and harvested.
RESULTS AND DISCUSSION
To assess the hypothesis that Wnt signaling regulates the expression of MITF-M/Mitf-M, we analyzed the effect of Wnt-3a protein on Mitf-M mRNA expression in cultured melanocytes. Accordingly, Melan-a immortalized melanocytes were treated with Wnt3a/L-CM containing Wnt-3a protein or neo/L-CM for 24 h (Fig. 1) . The treatment with Wnt3a/L-CM increased Mitf-M mRNA by 24 h (lane 1), whereas the treatment with neo/L-CM did not (lane 2). Thus, Wnt-3a induces the expression of endogenous Mitf-M mRNA, supporting the notion that Wnt signaling is involved in melanocyte differentiation.
Wnt signaling activates the target genes through the interaction of ␤-catenin and a member of the LEF-1/TCF transcription factors. The consensus DNA sequence recognized by LEF-1/TCF transcription factors is CTTTGA/TA/T (29) , and the MITF-M promoter contains a putative LEF-1/TCF-binding site, CTTTGAT (positions Ϫ199 to Ϫ193), which agrees with the consensus sequence (Fig. 2A) . The same sequence motif is conserved at a similar position in the mouse Mitf-M promoter. 2 To assess the function of the putative LEF-1/TCF-binding site in the MITF-M promoter, we compared the expression levels of pGL3-MITF/M in HMV-II human melanoma cells with those of pGL3-MITF/M(m195), containing the altered LEF-1/TCF site, CTTGTAT (Fig. 2B) . These base changes were expected to reduce the MITF-M promoter activity, because the Wnt signaling pathway is activated in many melanoma cells due to ␤-catenin mutation (36) . In fact, the expression level of pGL3-MITF/ 
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M(m195) was lower than that of pGL3-MITF/M, whereas the expression levels of these two constructs were similarly lower in HeLa cervical cancer cells. These results suggest that the CTTTGAT motif is involved in MITF-M promoter activity in melanoma cells. The significant luciferase activity detected with pGL3-MITF/M(m195) in melanoma cells may be due to the presence of other melanocyte-specific enhancers present in the MITF-M promoter.
We then performed cotransfection assays in HeLa cervical cancer cells to test the possibility that the LEF-1/TCF family is involved in regulation of the MITF-M promoter (Fig. 2C) . Expression of either LEF-1 or ␤-catenin significantly increased the luciferase activity under the control of the MITF-M promoter. The coexpression of ␤-catenin and LEF-1 synergistically increased the luciferase activity, which was higher than the degree of activation caused by LEF-1 or ␤-catenin. In contrast, the introduction of mutation at the putative LEF-1 site completely inhibited the increase in luciferase activity caused by LEF-1, ␤-catenin, or their combination (Fig. 2C) . These results suggest that the CTTTGAT motif of the MITF-M promoter represents a functional LEF-1-binding site.
To confirm whether LEF-1 protein binds to the CTTTGAT motif of the MITF-M promoter, we carried out EMSA. The in vitro translation of LEF-1 mRNA was confirmed by autoradiography of 35 S-labeled LEF-1 protein (data not shown). The synthetic LEF-1-binding site was specifically bound by the in vitro translated LEF-1 protein (Fig. 3, lane 1) . The formation of this complex was inhibited by competitor oligonucleotide containing the CTTTGAT motif but not by the mutant oligonucleotide containing the CTTGTAT motif (lanes 2 and 3) . Taken together, these results indicate that LEF-1 recognizes the CTT-TGAT motif of the MITF-M promoter. These results are consistent in part with the recent report showing that the LEF-1/ TCF-binding sites of the promoter region of the Nacre, a zebrafish homolog of MITF, is required for pigment cell-specific expression of a reporter gene in vivo (37) .
Finally, we assessed the effects of Wnt-3a protein on the MITF-M promoter activity in Melan-a cells (Fig. 4) . In this Melan-a cells were transfected with pGL3-MITF/M or pGL3-MITF/M(m195) and then treated with either Wnt3a/L-CM or neo/L-CM. Wnt3a/L-CM increased the expression of pGL3-MITF/M by about 2.5-fold. To confirm that this increase was dependent on Wnt signaling, we cotransfected the expression plasmid of a dominant-negative form of LEF-1, pRc/CMV-DN-LEF-1. The dominant-negative LEF-1 lacks the amino-terminal ␤-catenin interaction domain and is expected to inhibit Wnt signaling. The observed activation by Wnt3a/L-CM was completely inhibited when the dominant-negative LEF-1 was coexpressed. Furthermore, the expression level of pGL3-MITF/ M(m195) was lower than that of a wild-type construct, pGL3-MITF/M, and was not significantly increased by treatment with Wnt3a/L-CM. These results indicate that the LEF-1 site is necessary and sufficient for the activation of the MITF-M promoter by Wnt-3a signaling. The data all support the interpretation of a direct effect by Wnt-3a, but there is a possibility that a certain factor other than Wnt-3a in the conditioned medium from the Wnt-3a transfectants could contribute to the LEF-1-dependent activation. Further study with Wnt-3a neutralizing antibodies will be required to address this issue.
The MITF-M promoter is functional exclusively in melanocyte-lineage cells (6, 8) and is up-regulated via the separate cis-acting elements by PAX3 (19) and by ␣-melanocyte-stimulating hormone signaling (38) (see Fig. 2A ). Here, we provide evidence that Wnt-3a signal activates the MITF-M promoter through the LEF-1-binding site. Thus, multiple signals appear to converge on the MITF-M promoter, leading to the up-regulation of MITF-M expression, a key regulator for the melanogenesis enzyme genes. The expression levels of Pax3 mRNA were reduced in the double knock-out mouse of the Wnt-1 and Wnt-3a genes (24) . It is therefore conceivable that Wnt signals may also up-regulate Mitf-M/MITF-M expression through Pax3.
In summary, Wnt-3a protein induces Mitf-M mRNA expression in melanocytes and activates the MITF-M promoter by recruiting LEF-1 and ␤-catenin to the LEF-1-binding site. Thus, MITF-M/Mitf-M is a direct target gene of Wnt signaling in humans and mice.
